Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Betere behandeling van prostaatkanker door combinatie van bestralingstechnieken
feb 2017 | Radiotherapie, Uro-oncologie